Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Item No. 27767
![Histone H3K27Me3 (21-44)-GK-biotin (trifluoroacetate salt) (ATKAAR-K(Me3)-SAPATGGVKKPHRYRPG-GK(Biotin), H3(21-44)K27me3 Substrate, Histone H3 (21-44) (Lys27me3), [Lys(Me3)27]-Histone H3 (21-44)-GK(Biotin))](https://cdn2.caymanchem.com/cdn/productImages/27767.png)
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Histone H3K27Me3 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.1 and 3.2 sequences. It is trimethylated at lysine 27 and biotinylated via a C-terminal GK linker. Trimethylation of histone H3 at lysine 27 is associated with gene silencing.1 It is involved in tumor progression through its regulation by enhancer of zeste homolog 2 (EZH2) and transcriptional repression of tumor suppressor genes.2,3 Levels of H3K27Me3 are reduced in 293 T-REx cells containing EEDR236T and SUZ12G610V mutations and in lymphoblastoid cells isolated from patients with Weaver syndrome, a rare overgrowth disorder characterized by EZH2, EED, or SUZ12 mutations, cancer susceptibility, and various distinctive physical features.4 Histone H3K27Me3 (21-44)-GK-biotin has been used as a substrate for histone lysine demethylases (KDMs) to determine substrate specificity.5
WARNING This product is not for human or veterinary use.
1. H3K9me3-
2. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 18(11), 1771-1779 (2011).
3. Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential. Biomark. Res. 6, 10 (2018).
4. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome. Hum. Mutat. 38(6), 637-648 (2017).
5. Cancer-